ShareValue scores for LYKALABS.NSE: Valuation 57, Quality 31, Growth 45, Health 47.

LYKALABS.NSE
NSE

Lyka Labs Limited

₹68.10(-2.70%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 17%
Valuation
57
Fair Value
Price vs Value
Quality
31
Weak
Business Strength
Growth
45
Moderate
Revenue & Earnings
Health
47
Moderate
Financial Stability
Momentum
60
Bullish
Price Trend

Company Details

About

Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, anti-fungal and bacterial, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports its products. The company was incorporated in 1976 and is based in Mumbai, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026